As of June 30, 2025, the company reported C$14.6M in cash and cash equivalents, projecting a cash runway through key milestones and into the first quarter of 2026. “We have turned the corner from proof-of-concept studies and will be sprinting toward regulatory clarity for the remainder of the year,” said Jared Kelly, Chief Executive Officer of Oncolytics (ONCY). “As we shore up our intellectual property, get a clear registration path for pelareorep, and allow our GOBLET data to mature, we will establish our position as the only platform immunotherapy in gastrointestinal tumors.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCY:
- Oncolytics voluntarily delists common shares from Toronto Stock Exchange
- Oncolytics Biotech to Hold Virtual Annual Meeting and Announce Q2 Financial Results
- ONCY Upcoming Earnings Report: What to Expect?
- Buy Rating on Oncolytics Biotech: Strategic Focus on Pancreatic Cancer and Undervalued Stock Potential
- Oncolytics Biotech Engages FDA for Pivotal Pancreatic Cancer Study